TY - JOUR
T1 - Legionella Antibiotic Susceptibility Testing
T2 - Is it Time for International Standardization and Evidence-Based Guidance?
AU - Portal, Edward
AU - Descours, Ghislaine
AU - Ginevra, Christophe
AU - Mentasti, Massimo
AU - Afshar, Baharak
AU - Chand, Meera
AU - Day, Jessica
AU - Echahidi, Fedoua
AU - Franzin, Laura
AU - Gaia, Valeria
AU - Lück, Christian
AU - Meghraoui, Alaeddine
AU - Moran-Gilad, Jacob
AU - Ricci, Maria Luisa
AU - Lina, Gerard
AU - Uldum, Søren
AU - Winchell, Jonas
AU - Howe, Robin
AU - Bernard, Kathryn
AU - Spiller, Owen B.
AU - Chalker, Victoria J.
AU - Jarraud, Sophie
N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
PY - 2021/5
Y1 - 2021/5
N2 - Legionella pneumophila, a Gram-negative bacillus, is the causative agent of Legionnaire's disease, a form of severe community-acquired pneumonia. Infection can have high morbidity, with a high proportion of patients requiring ICU admission, and up to 10% mortality, which is exacerbated by the lack of efficacy of typical empirical antibiotic therapy against Legionella spp. The fastidious nature of the entire Legionellaceae family historically required inclusion of activated charcoal in the solid medium to remove growth inhibitors, which inherently interferes with accurate antimicrobial susceptibility determination, an acknowledged methodological shortfall, now rectified by a new solid medium that gives results comparable to those of microbroth dilution. Here, as an international Legionella community (with authors representing various international reference laboratories, countries and clinical stakeholders for diagnosis and treatment of legionellosis), we set out recommendations for the standardization of antimicrobial susceptibility testing methods, guidelines and reference strains to facilitate an improved era of antibiotic resistance determination.
AB - Legionella pneumophila, a Gram-negative bacillus, is the causative agent of Legionnaire's disease, a form of severe community-acquired pneumonia. Infection can have high morbidity, with a high proportion of patients requiring ICU admission, and up to 10% mortality, which is exacerbated by the lack of efficacy of typical empirical antibiotic therapy against Legionella spp. The fastidious nature of the entire Legionellaceae family historically required inclusion of activated charcoal in the solid medium to remove growth inhibitors, which inherently interferes with accurate antimicrobial susceptibility determination, an acknowledged methodological shortfall, now rectified by a new solid medium that gives results comparable to those of microbroth dilution. Here, as an international Legionella community (with authors representing various international reference laboratories, countries and clinical stakeholders for diagnosis and treatment of legionellosis), we set out recommendations for the standardization of antimicrobial susceptibility testing methods, guidelines and reference strains to facilitate an improved era of antibiotic resistance determination.
UR - http://www.scopus.com/inward/record.url?scp=85104899902&partnerID=8YFLogxK
U2 - 10.1093/jac/dkab027
DO - 10.1093/jac/dkab027
M3 - Article
C2 - 33608737
VL - 76
SP - 1113
EP - 1116
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
SN - 0305-7453
IS - 5
ER -